CVS Health Corp (CVS) (2024)

Morningstar Rating

Unlock

Stock XNYS Rating as of Jun 7, 2024

$60.28 −1.50(2.43%)

View Full Chart

As of Jun 10, 2024 11:00pm Delayed Price Post-Trading:$60.30 0.00

Unlock our analysis with Morningstar Investor

Start Free Trial

Company Report

View Archive

CVS Facing Near-Term Headwinds in Medicare Advantage and PBM

Julie Utterback May 8, 2024

CVS aims to be the most customer-centric health company in the United States and has spent over a decade positioning itself as a managed care leader, with the acquisitions of pharmacy benefit manager Caremark (2007), insurance provider Aetna (2018), and healthcare service provider Oak Street (2023) defining its strategic direction. CVS' top-tier retail pharmacy, health insurer, and PBM franchises create the potential to improve health outcomes and even bend the healthcare cost curve for its clients, especially if it can align incentives by owning healthcare service providers, as well.

Read Full Report

Price vs Fair Value

See Also
CVS Health Corporation (CVS) Latest Stock News & Headlines - Yahoo Finance

View History

CVS is trading at a 361% premium.

Price

$61.78

Jun 7, 2024

Fair Value

$37.00

May 1, 2024

Uncertainty

Medium

1-Star Price: $734.86
5-Star Price: $68.40
Economic Moat: Zlmmbyw
Capital Allocation: Ycfdyqdm

Bulls Say, Bears Say

Bulls

CVS' diverse operations create the opportunity to view a patient more holistically by managing both medical and pharmacy benefits, which could lead to revenue and cost synergies for the organization.

Bears

Healthcare reform will likely remain a recurring political topic until universal, affordable coverage is achieved in the US, and CVS' stock may experience volatility if scenarios that threaten its prospects gain traction.

Is it the right time to buy, sell, or hold?

Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CVS is a good fit for your portfolio.

Get 7 Days Free

News

View All

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVS Health Corporation - CVS
CVS Currently Up Eight Consecutive Days, on Track for Longest Winning Streak Since December 2021 — Data Talk
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of CVS Health Corporation - CVS
CVS on Pace for Largest Percent Increase Since August 2022 — Data Talk
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVS Health Corporation - CVS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of CVS Health Corporation - CVS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVS Health Corporation - CVS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of CVS Health Corporation - CVS

Trading Information

Previous Close Price: $61.78
Day Range: $59.91–61.53
52-Week Range: $52.77–83.25
Bid/Ask: $60.29/$60.30
Market Cap: $75.67 Bil
Volume/Avg: 10.6 Mil/12.1 Mil

Key Statistics

Price/Earnings (Normalized): 7.87
Price/Sales: 0.22
Dividend Yield (Trailing): 4.11%
Dividend Yield (Forward): 4.31%
Total Yield: 8.01%

Company Profile

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

Sector: Healthcare
Industry: Healthcare Plans
Stock Style Box: Large Value
Total Number of Employees: 300,000
Website: https://www.cvshealth.com

Competitors

Humana Inc HUM
Elevance Health Inc ELV
The Cigna Group CI
UnitedHealth Group Inc UNH
Walgreens Boots Alliance Inc WBA

Valuation

Metric	CVS	HUM	ELV
Price/Earnings (Normalized)	7.87	14.76	15.72
Price/Book Value	1.05	2.63	3.09
Price/Sales	0.22	0.40	0.74
Price/Cash Flow	6.51	12.62	13.91

Price/Earnings

CVS

HUM

ELV

Financial Strength

Metric	CVS	HUM	ELV
Quick Ratio	0.54	—	—
Current Ratio	0.81	—	—
Interest Coverage	4.55	7.86	8.49

Quick Ratio

CVS

HUM

ELV

Profitability

Metric	CVS	HUM	ELV
Return on Assets (Normalized)	4.07%	5.46%	7.36%
Return on Equity (Normalized)	13.68%	17.15%	20.87%
Return on Invested Capital (Normalized)	7.90%	11.21%	13.85%

Return on Assets

CVS

HUM

ELV

See how this stock stacks up to its competitors with Morningstar Investor